

Ionpath
High-Definition Spatial Proteomics

QUANTITATIVE, SPATIAL SINGLE-CELL PHENOTYPE MAPPING

Could you be leaving critical info on the table with your current tissue analysis methods?

The rapid pace of innovation in immuno-oncology demands deeper understanding of the tumor microenvironment. Yet, available methods fall short.

- IHC, the current gold standard method is qualitative and does not provide the depth needed to meet the demands of immuno-oncology development
- Most multiplex techniques, including spatial transcriptomics, promise new insights but bury researchers in data that is not actionable and lack clinical grade repeatability

---

Ionpath delivers the next generation of tissue analysis: High-Definition Spatial Proteomics

- Achieve comprehensive, quantitative single-cell phenotype mapping at subcellular resolution
- Identify key mechanisms of action with clinical grade repeatability
- Reveal actionable insights, identify responder populations, or predict patient response



GAIN DEEPER UNDERSTANDING OF THE TUMOR MICROENVIRONMENT



REVEAL ACTIONABLE INSIGHTS

DELIVERING ON THE PROMISE OF SPATIAL PROTEOMICS

IONPATH

Ionpath | HIGH DEFINITION SPATIAL PROTEOMICS

GET THE MOST UNDERSTANDING OUT OF YOUR PRECIOUS HUMAN TISSUE SAMPLES

Multiplexed ion beam imaging, MIBI™, is the only technology that delivers the information needed for understanding the tumor microenvironment with the throughput and reproducibility required for clinical studies.

- Enumerate immune cell populations
- Quantify checkpoint marker expression on a single-cell basis
- Analyze spatial interactions between target and effector cells



CELL CLASSIFICATION | PROTEIN EXPRESSION | SPATIAL ANALYSIS

LEVERAGE OUR MULTI-DISCIPLINARY EXPERT TEAM TO ACCELERATE YOUR PROJECT

- The world-class, multi-disciplinary team at Ionpath provides end-to-end Spatial Proteomic Services to support your tissue analysis needs.
- Projects defined and planned in collaboration with expert scientific team
- Rigorous validation with multiple layers of control ensures consistent data quality across large sample cohorts
- Expert data analysis with relevant, actionable information provided in a usable report form

ACTIONABLE INSIGHTS



RAPID ADOPTION BY LEADING ORGANIZATIONS

- Leading pharmaceutical and biotech companies
- Top-tier academic and cancer research centers

Dana-Farber Cancer Institute · The University of Texas MD Anderson Cancer Center · Memorial Sloan Kettering Cancer Center · Walter+Eliza Hall Institute of Medical Research · UCSF University of California San Francisco · Stanford University · McMaster University · Weizmann Institute of Science · Denver CU IN THE CITY · University of Calgary · dkfz. German Cancer Research Center · University of Minnesota

SELECT PUBLICATIONS WITH MIBI-ENABLED RESEARCH

Predictive spatial signatures of breast cancer progression | Risom *et al.*, *Cell* 2022 (view)
Immunoregulatory landscape of tuberculosis granulomas | McCaffrey *et al.*, *Nature Immunol.* 2022 (view)
Multiplexed Ion Beam Imaging: Insights into Pathology | Liu, *et al., Ann. Rev. Pathology* 2022 (view)
An atlas of human small cell lung cancer | Chan *et al.*, *Cancer Cell* 2021 (view)
An IFN-γ-driven inflammatory state in nivolumab-associated gastritis revealed by MIBI | Ferrian *et al.*, *Cell Reports Medicine* 2021 (view)
Reproducible, high-dimensional imaging in archival human tissue by MIBI | Liu *et al.*, *Biorxiv* 2021 (view)
Multimodal analysis of squamous cell carcinoma | Ji *et al.*, *Cell* 2020 (view)
Metabolic profiling of human cytotoxic T-cells | Hartmann *et al.*, *Nat. Biotechnol.* 2020 (view)
Tumor microarchitecture in triple negative breast cancer | Keren *et al.*, *Cell* 2018 (view)

Ionpath | research@ionpath.com | 833.466.7284

IONPATH